$655 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 11 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 85.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ODT | Buy | ODONATE THERAPEUTICS INC | $297,880,000 | +45.6% | 15,514,566 | +1.8% | 45.48% | +22.8% |
| RCKT | ROCKET PHARMACEUTICALS INC | $162,627,000 | +139.9% | 2,965,485 | 0.0% | 24.83% | +102.4% | |
| APVO | New | APTEVO THERAPEUTICS INC | $64,504,000 | – | 1,760,000 | +100.0% | 9.85% | – |
| ANAB | ANAPTYSBIO INC | $56,517,000 | +45.8% | 2,628,678 | 0.0% | 8.63% | +23.0% | |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $36,493,000 | -3.7% | 9,405,490 | 0.0% | 5.57% | -18.8% | |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $11,297,000 | +12.0% | 650,000 | +18.2% | 1.72% | -5.5% |
| VINCU | New | VINCERA PHARMA INCunit 12/24/2025 | $9,630,000 | – | 500,000 | +100.0% | 1.47% | – |
| RLMD | Sell | RELMADA THERAPEUTICS INC | $6,414,000 | -65.9% | 200,000 | -60.0% | 0.98% | -71.2% |
| BCTG | BCTG ACQUISITION CORP | $5,363,000 | +10.4% | 468,750 | 0.0% | 0.82% | -6.8% | |
| EQ | New | EQUILLIUM INC | $3,210,000 | – | 600,000 | +100.0% | 0.49% | – |
| VINCW | New | VINCERA PHARMA INC*w exp 12/24/202 | $1,090,000 | – | 330,205 | +100.0% | 0.17% | – |
| Exit | TENAX THERAPEUTICS INC | $0 | – | -460,000 | -100.0% | -0.13% | – | |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -112,880 | -100.0% | -0.14% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -178,688 | -100.0% | -0.32% | – |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -191,426 | -100.0% | -0.34% | – |
| EGRX | Exit | EAGLE PHARMACEUTICALS INC | $0 | – | -62,262 | -100.0% | -0.48% | – |
| LSACU | Exit | LIFESCI ACQUISITION CORPunit 03/31/2025 | $0 | – | -500,000 | -100.0% | -1.23% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -700,000 | -100.0% | -1.65% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -1,246,121 | -100.0% | -2.28% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -1,578,795 | -100.0% | -2.70% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -160,000 | -100.0% | -2.92% | – |
| BIO | Exit | BIO RAD LABS INCcl a | $0 | – | -40,000 | -100.0% | -3.73% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -599,091 | -100.0% | -7.05% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -2,896,904 | -100.0% | -7.77% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.